Compare CPK & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPK | NUVB |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 1995 | N/A |
| Metric | CPK | NUVB |
|---|---|---|
| Price | $136.74 | $5.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $140.00 | $11.44 |
| AVG Volume (30 Days) | 99.6K | ★ 4.0M |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 13.50 | N/A |
| EPS | ★ 5.97 | N/A |
| Revenue | ★ $930,000,000.00 | N/A |
| Revenue This Year | $1.04 | $659.84 |
| Revenue Next Year | $4.06 | $180.43 |
| P/E Ratio | $22.87 | ★ N/A |
| Revenue Growth | ★ 18.14 | N/A |
| 52 Week Low | $115.24 | $1.57 |
| 52 Week High | $140.59 | $9.75 |
| Indicator | CPK | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 64.54 | 47.39 |
| Support Level | $123.24 | $5.22 |
| Resistance Level | $138.30 | $6.22 |
| Average True Range (ATR) | 3.60 | 0.31 |
| MACD | 0.24 | 0.09 |
| Stochastic Oscillator | 84.40 | 69.18 |
Chesapeake Utilities Corp is a diversified energy delivery company that is engaged in natural gas transmission and distribution, electricity generation and distribution, propane gas distribution, mobile compressed natural gas utility services and solutions and other businesses. The company operates in two reportable segments, Regulated Energy and Unregulated Energy. The company's natural gas and electric distribution operations in Delaware, Maryland and Florida are subject to regulation by PSC. Eastern Shore, its natural gas transmission is subject to regulation by the FERC and Peninsula Pipeline and Aspire Energy Express, its intrastate pipeline subsidiaries, are subject to regulation by the Florida PSC and Public Utilities Commission of Ohio, respectively.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.